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doi:10.1016/j.ejvs.2009.11.027Abstract Objectives: This study aims to compare the efficacy and side effects of foam scler-
otherapy of the saphenous veins with or without post-treatment compression using graduated
elastic stockings.
Design: This is a prospective open randomised controlled trial conducted in two centres.
Patients and methods: Sixty patients with incompetent great (GSV) or small saphenous veins
(SSV) underwent ultrasound-guided foam sclerotherapy. Randomisation was conducted imme-
diately after sclerotherapy to two parallel groups, one (CG) with compression stockings
(15e20 mmHg worn during the day, for 3 weeks) and the other (WCG) without compression.
Efficacy of sclerotherapy and all of the side effects were assessed, including side effects in
the treated region.
On days 14 and 28, clinical and duplex ultrasound (DUS) assessments were performed by
independent experts. Patients also completed quality of life (QOL), symptom questionnaires
and provided satisfaction scores.
Results: Five men and 55 women ranging in age from 32 to 78 (mean 57 years) years were
included: 29 in the WCG and 31 in the CG group. On day 28, abolition of venous reflux and
occlusion of the vein was obtained in 100% of the cases in both groups. The length of the
occluded vein was the same in both groups (mean 36 cm for the GSV and 30 cm for the SSV)
as was the mean diameter of the occluded vein (5 mm). Symptoms and QOL questionnaires
showed equivalent improvement in both groups on day 28 compared to pre-treatment assess-
ments. Side effects were few with no statistical difference between the two groups. Patient
satisfaction scores were high in both groups for the outcome of sclerotherapy results, and good
or very good for compression in 50% of the CG cases.31 43 34 34; fax: þ33 231 43 30 30.
u (C.M. Hamel-Desnos).
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 Patient with a history of menta
manner and compliant with the
 Voluntary Consent Form unsigne
 Patients with isolated sapheno-
 Patients with post-surgical recu
recurrence in the thigh or calf.
 Patients with chronic liver disea
 Renal failure (creatinine > 150
 Pregnant or nursing women.
 Women with a risk of pregnancy
 Physical or geographical imposs
 Patients with known progressive
 Patient with uncontrolled hyper
 Patient suffering from respirato
 Patient with a history of deep v
 Patients with known inherited o
 Patient with alcohol intolerance
 Patient with known allergy to L
 Patients with known patent fora
 Patient presenting in the past w
 Lycra allergy.
 Inability to apply elastic compreConclusion: We found no difference between compression and control groups when comparing
efficacy, side effects, satisfaction scores, symptoms and QOL. Further studies are required to
establish the role of compression in sclerotherapy and to evaluate other compression strate-
gies.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Compression after sclerotherapy for saphenous truncal
incompetence is recommended by experts, but there is little
good-quality scientific evidence to support this.1 The use
of compression may improve the results of sclerotherapy
by reducing side effects, such as deep vein thrombosis,
thrombophlebitis, inflammation, pain, pigmentation and
matting. It may also reduce the amount of endoluminal
thrombus leading to more rapid occlusion of a treated vein
and increasing the efficacy of treatment.2 No randomised
clinical trial has been published comparing the outcome of
the treatment of saphenous varices with and without
compression.
The aim of this study was to assess the effect of grad-
uated elastic compression stockings on the outcome of
foam sclerotherapy for varices arising from the great and
small saphenous trunks in a randomised controlled trial.Patients and Methods
The study design was a randomised, open, prospective,
two-centre study with two parallel arms: one group without
compression (WCG) and one group with compression (CG)
using stockings (Class 2 French standard 15e20 mmHg),
worn during the day for 3 weeks following treatment.
Patients considered for inclusion in this study were those
presenting for treatment of symptomatic varicose veins.l or psychiatric disorder or any fa
study.
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femoral junction incompetence w
rrence of varices in the region of
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mmol/l).
during treatment (absence of co
ibility of participation in the stud
malignant disease.
tension.
ry or cardiac failure.
ein thrombosis.
r acquired coagulopathy.
or having taken a blocking degra
AUROMACROGOL 400.
men ovale (PFO).
ith migraine or visual or other ne
ssion (e.g. osteoarthritis).One of the investigation centres was a university hospital
(Brest, France), the other was private clinic (Caen, France).
In total, 60 patients were included, of both sexes and
varying ethnicity, with a minimum age of 18 years, and who
suffered from incompetence of the great (GSV) or small
(SSV) saphenous vein.
Patients were examined by physicians skilled in the
management of venous disease. A history was taken and
clinical examination performed allowing assessment of the
distribution of varices as well as assignment of the correct
clinical, etiologic, anatomic, and pathophysiologic data
(CEAP) clinical class. DUS was undertaken with the patient
in the standing position to assess the competence of deep
and superficial veins and establish the extent of saphenous
incompetence. Patients were considered suitable for
treatment by foam sclerotherapy when the trunk diameter
was a maximum of 8 mm for the GSV and 6 mm for the SSV
with venous reflux lasting at least 1 s. CEAP classes, which
were included in this study, were C2seC6, Ep, As2, 4, and
Pr with level II examination.3 The exclusion criteria are
listed in Table 1.
The objectives were to compare the efficacy and side
effects of foam sclerotherapy of the saphenous veins with
or without compression stockings. The main outcome
measure was ultrasound-assessed obliteration of venous
reflux in the treated saphenous trunk 28 days after treat-
ment. Secondary outcome measures included assessment of
adverse events such as pain, thrombophlebitis, pigmenta-
tion and telangiectatic matting.ctor limiting the ability to participate in an informed
ithout saphenous trunk incompetence of the thigh.
the great saphenous vein or small saphenous vein without trunk
ntraception).
y.
dation of ethanol (Espe´ral for example) in the previous month.
urological disorders after sclerosing foam injection.
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Committee (Nord Ouest III CPP e.g., Comite´ de Protection
des Personnes, registered on 2 December 2006 under No. N
2006e22). It complies with the Declaration of Helsinki
(1964) according to its latest version (Hong Kong, 1989).
Patients who gave informed written consent for their
inclusion in the study were investigated further. The scle-
rosant used was polidocanol (AETOXISCLEROL, manufac-
tured by Laboratoires Kreussler, Paris, France).
Sclerosant foam was obtained using a sterile disposable
syringe kit including sterile air and the TURBOFOAM
machine (Kreussler Pharma, Wiesbaden, Germany). The
sclerosant liquid and air mixture was 1 þ 4 (one volume of
Aetoxiscle´rol þ four volumes of air). The characteristics of
the foam obtained were standardised and these data have
already been assessed and published.4
Sclerotherapy
Amaximumof three sclerotherapy sessionswere permitted to
obtain saphenous vein occlusion. The sclerotherapy was
guided by ultrasound and performed by direct puncture with
needle,with thepatient lying recumbent.Thevolumeof foam
allowed per session was between 2.5 ml and 8 ml for the GSV
and between 2 ml and 5 ml for the SSV.5 The concentration
could be 1e2%, depending on the diameter of the vein.6 No
concomitant treatment was performed on other varices.
Randomisation was conducted after sclerotherapy using
a randomisation list stratified by centre and type of
saphenous vein (small or great) provided by the statistician.
For CG patients, there was an interval of 5e10 min after
sclerotherapy before the investigator applied the
compression stockings (patient still lying on the treatment
couch), to avoid possible dislocation of the foam column.7
Compression hosiery was thigh length for GSV and knee
length for SSV.
Follow-up examinations were performed during the
28-day period following treatment.
Patients were reviewed by both clinical and duplex
ultrasound (DUS) examinations on days 7, 14 and 28. The aim
of the day 7 examination was to investigate the possibility
that deep vein thrombosis had arisen following treatment.
Visits and assessments on days 14 and 28 were per-
formed by an independent expert who was not a member
of the clinical team at either clinic. Patients on day
0 (inclusion day) and on day 28 completed a quality-of-life
(QOL) self-questionnaire, CIVIQ 2 (Chronic Venous Insuffi-
ciency Questionnaire), consisting of 20 questions using
four criteria: pain, physical, social and psychological
effects.8 They also completed further questionnaires
about their symptoms (heavy-leg sensation, pain, oedema,
paraethesia and cramps) on days 0, 14 and 28. On days 7,
14 and 28, the practitioner undertook a clinical examina-
tion and recorded symptoms arising following treatment.
Patients themselves completed a questionnaire evaluating
side effects in the region of sclerosis, such as pain,
inflammation, ecchymosis, induration, pigmentation and
matting. A score was assigned for each criterion, which
were summed to produce a total score. On day 28, the
investigator and the patients also separately completed
a satisfaction score, but only the CG patients provided
a satisfaction score for compression.The criteria for efficacy of sclerotherapy were abolition
of saphenous reflux, length of the occlusion and diameter
of the occluded vein as assessed by B-mode ultrasound
imaging.
Length of occlusion of saphenous vein was the main
outcome measure in this study. The main criteria used to
assess the severity of side effects were QOL and satisfaction
scores and the total score of side effects in the treated
region. The secondary criteria were the consumption of
analgesics and/or anti-inflammatory drugs, tolerance and
compliance with compression treatment and adverse events
of sclerotherapy other than those previously described. A
comparison was made between the scores obtained from the
compression and non-compression groups.
Statistical methods
In the absence of prior data, the number of subjects was set
at 30 per treatment group, making 60 subjects in total. The
sample size of 30 subjects per group was chosen arbitrarily
but appears to be sufficient for obtaining a satisfactory and
sufficiently accurate assessment of the main parameters.
Statistical calculations were made using SAS software.
The efficacy analysis focussed on the two study populations
(ITT and PP, i.e., intention to treat and per protocol). With
respect to the intra-group analysis (before/after treatment
in a group) and inter-group analysis (with compression
versus without compression) the paired Student’s t-test (or
Wilcoxon paired test for non-normally distributed data) was
performed on the quantitative variables. Descriptors used
to report data are the mean and standard deviation.
Tolerance was assessed in all patients included in the
trial and any side effects were reported with a descriptive
method.
Results
Between January and June 2007, 60 patients (five men and 55
women) ranging in age from 32 to 78 years (median Z 57
years) were included, 29 in group WCG and 31 in group CG.
The groups were homogeneous, except with respect to age,
where therewas a statistically significant difference,with the
CG group being older than the WCG: mean age being 53 SD 14
for WCG and 61 SD 11 for CG (pZ 0.0178) (Table 2). The right
limb was affected in 60% of patients. The GSV was involved in
60% of cases and the SSV in 40%. The average diameter of the
veins treated was 5.8 mm for the GSV and 5.1 mm for the SSV.
There was no significant difference between the two groups
(Table 2). The mean CEAP clinical class was 2.6 (range 2e6).
Sclerotherapy
DUS showed that 100% efficacy of treatment was achieved
with abolition of reflux and occlusion of the vein at day 28
in both treatment groups. The protocol for the study
permitted a total of three treatment sessions to achieve
saphenous occlusion. In fact, only one treatment session
was necessary to achieve the intended outcome and
employed only moderate volumes of foam. On average 4 ml
of foam was used for the GSV and 3.6 ml for the SSV (range
2.5e7.5 ml). In 90% of the patients the concentration used
Table 2 General data.
Without compression
(WCG)
With compression
(CG)
TOTAL p
Patients (n) 29 31 60
Age 53 SD 14
(range 33e76)
61 SD 11
(range 32e78)
57 SD 12
(range 32e78)
0.018
Men Women 1 (3%) 28 (97%) 4 (13%) 27 (87%) 5 (8%) 55 (92%) N.S.
Height (cm) 163 SD 6.8 165 SD 6.5 164. SD 6.6 N.S.
Weight (kg) 69 SD 12 72 SD 13 70 SD 12 N.S.
BMI 26 SD 4.5 27 SD 4.2 26 SD 4.3 N.S.
Right Lower Limb 19 (66%) 17 (55%) 36 (60%) N.S.
Left Lower Limb 10 (35%) 14 (45%) 24 (40%)
GSV 17 (59%) 19 (61%) 36 (60%) N.S.
SSV 12 (41%) 12 (39%) 24 (40%)
GSV diameter (mm) 5.6 SD 1.1
(range 3.5e8.0)
5.9 SD 1.1
(range 4.0e7.5)
5.8 SD 1.1
(range 3.5e8.0)
N.S.
SSV diameter (mm) 4.9 SD 0.9
(range 3.5e6.0)
5.3 SD 1.2
(range 4.0e7.5)
5.1 SD 1.0
(range 3.5e7.5)
N.S.
Polidocanol Concentration (%) Mean 1.0 SD 0.2 1.2 SD 0.4 1.1 SD 0.3 0.06
Volume (mL) Mean 4.0 SD 1.4
(range 2.5e7.5)
3.6 SD 1.2
(range 2.5e7.5)
3.8 SD 1.3
(range 2.5e7.5)
N.S.
Length of occlusion (cm) Day 7 33 SD 12 30 SD 12 N.S.
Day 14 34 SD 12 29 SD 10 N.S.
Day 28 35 SD 11 30 SD 10 0.08
Diameter of occluded veins (mm) Day 7 5.3 SD 1.4 5.7 SD 1.2 N.S.
Day 14 5.3 SD 1.4 5.5 SD 1.4 N.S.
Day 28 5.0 SD 1.1 5.0 SD 1.2 N.S.
BMI Z Body Mass Index; GSV Z Great Saphenous Vein; SSV Z Small Saphenous Vein.
Data are expressed as mean and standard deviation (SD) for continuous variables and number of limbs (percentage).
Foam Sclerotherapy with or without Compression 503was 1%; 2% was used in only six of the 60 cases (10%). The
average occlusion length was 36 cm for the GSV (CG: 35 and
WCG: 37) and 30 cm for the SSV (CG: 26 and WCG: 33). The
time taken to complete treatment sessions in the CG and
WCG groups was similar. The average diameter of the
occluded veins was similar in both treatment groups at 14
and 28 days following treatment. The application of
compression had no measurable effect on vein diameter
following sclerotherapy (Table 2).
Assessments of QOL investigated four criteria: impact of
pain, social impact, physical functioning and psychological
dimensions. The overall score decreased compared with
the pre-treatment baseline assessments and showed equal
improvements in both groups (Table 3).
Assessment of symptoms reported by patients included
evaluation of heavy-leg sensation, pain in legs, oedema of
the lower limbs, paresthaesia and cramp. Symptoms
improved after treatment to an equal extent in both
treatment groups (Table 3).
The patients reported their opinion of the outcome as
satisfaction scores. After 14 days following sclerotherapy,
all of the WCG patients found the treatment to be effective
or very effective compared with 93% in the CG group (N.S.).
After 28 days, 97% of WCG group found the treatment
effective or very effective compared to 100% of the CG
group (Table 3).
The independent investigators scored the patient’s
satisfaction scale of 1e10. The range of satisfaction was
8.2e9, so most patients appeared to be content with the
outcome of treatment. However, on day 14 and on day 28,satisfaction was greater in the WCG than in the CG group,
with a statistically significant difference between the two
groups: p Z 0.0046 at day 14 and p Z 0.0009 at days 28.
Patients in the CG group assessed the compression treat-
ment and reported that 50% were ‘very satisfied’ or
‘satisfied’, 37% were ‘moderately satisfied’ and 13% ‘not at
all satisfied’. (Table 3)
Side effects in the treated region (Table 4)
Pain
Comparing the absence of pain at days 14 and 28 between
the two groups, no significant difference was apparent.
For the mild and moderate levels of pain, there was very
little difference between the two groups at day 14. Only
one patient reported severe pain at the 14-days assess-
ment (in the CG group), and no patient reported severe
pain at day 28.
Inflammation
Few patients exhibited signs of inflammation at either day
14 or 28, regardless of the treatment group and there was
no difference between groups.
Ecchymosis
The difference between the two groups was not statisti-
cally significant at either day 14 or 28.
Induration
At 28 days following treatment, mild induration was
observed in nine patients (four in WCG and five in CG),
Table 3 Quality of Life Global Score; Patients’ symptoms; Patient satisfaction score.
Without compression WCG With compression CG
Quality of Life Global score e Difference from pre-treatment assessment:
Day 14
N 21 22
Mean 9.0 SD 9.9 5.5 SD 10
p 0.0005 0.02
Day 28
N 24 23
Mean 11 SD 14 9.4 SD 10
p 0.0010 0.0002
Patients’ symptoms e Rate of improvement at day 28
Heavy-leg sensation 55% 67%
Pain 59% 70%
Oedema of the lower limbs 52% 50%
Paresthesias 45% 57%
Cramp 55% 37%
Patient satisfaction score e Patients’ sclerotherapy treatment assessment
Day 14 (p 0.08)
Moderately effective N Z 0 N Z 2 (7%)
Effective N Z 9 (31%) N Z 13 (43%)
Very Effective N Z 20 (69%) N Z 15 (50%)
Total N Z 29 (100%) N Z 30 (100%)
Day 28 (p 0.39)
Moderately effective N Z 1 (3.4%) N Z 0
Effective N Z 9 (31%) N Z 8 (27%)
Very Effective N Z 19 (66%) N Z 22 (73%)
Total N Z 29 (100%) N Z 30 (100%)
Patient satisfaction score e Patients’ compression evaluation e day 14
Not Effective N Z 4 (13%)
Moderately Effective N Z 11 (37%)
Effective N Z 8 (27%)
Very Effective N Z 7 (23%)
Total N Z 30 (100%)
504 C.M. Hamel-Desnos et al.moderate induration in three patients (two in WCG and one
in CG) and one major induration in CG. The rate of absence
of induration was 79% for WCG and 76% for CG (N.S.).
Pigmentation
At day 28, the presence of pigmentation was observed in
only three patients (one in WCG, and two in CG), no
statistically significant difference being observed between
the two groups (p Z N.S.).
Matting
At day 28, six patients in WCG and four patients in CG
indicated mild or moderate matting. There was no matting
for all other patients and absence of matting rate was 79%
for WCG and 86% for CG (N.S.).
The total number of side effects of sclerotherapy was
similar in the two treatment groups. Episodes of thrombo-
phlebitis, with extension of sclerosis to saphenous
tributaries, were few with no difference between the two
groups (three cases in each) (Figs. 1 and 2).Few patients took analgesics during the study: four at
day 14 follow-up in each group, two at day 28 in the WCG
group and three in the CG group (N.S.).
Compliance with the compression regime was poor. The
mean number of days for wearing elastic compression was
11 for a total of 21 scheduled days. Only 40% of patients
wore compression stockings every day. The reasons for not
wearing the stockings were: discomfort for 32%, discomfort
and painful tightness for 11%, itching for 9%, irritation for
6%, swelling and cold feet for 4% each. Other reasons
accounted for 37%.
Other adverse events (Table 4)
No deep vein or superficial thrombosis was identified in the
DUS. There were two cases of medial gastrocnemius venous
thrombosis (in CG). These were minor and asymptomatic
and were detected during routine DUS examination per-
formed on day 7. Both patients had had SSV sclerotherapy
with POL foam 1% (3 ml for one case and 4 ml for the other).
No specific treatment was given.
Table 4 Sclerotherapy side effects. Without compression group (WCG) (n)/With compression group (CG) (n). NB it should be
noted that a same patient may have several concomitant side effects (for example a patient presenting with thrombophlebitis
may describe induration, inflammation and matting and so will appear in several columns).
Immediate
(<24 h)
Dizziness0
0
Cough, chest
symptoms
0
Neurological
complications
0
Visual
disturbance,
migraine
WCG 1; CG0
Pain
0
Allergy
0
Others
0
Day O to 28
Local reactions
Ecchymosis
Day 28
(mild or
moderate)
WCG 1; CG 2
Hæmatoma: 0
Inflammation
WCG 3; CG 3
Induration
Moderate
WCG 2; CG 1
Major
WCG 0; CG1
Pain Day 28
(moderate)
WCG 3;
CG 1
Pigmentation
WCG 1; CG 2
Matting
(mild or
moderate)
WCG 6;
CG 4
Thrombophlebitis
WCG 3; CG 3
Day 0e28 DUS
examination
Gastrocnemius
vein thrombosis
WCG 0; CG 2
SVT
0
DVT
0
No link to
treatment
Acute coronary
syndrome CG 1
Various (viral
tonsillitis,
rhinitis sinusitis)
DUS Z Duplex UltraSound, SVT Z superficial vein thrombosis; DVT Z deep vein thrombosis.
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(thrombus diameter on day 7Z 4 mm) and the other was on
a clear downward trend (thrombus diameter on day
7 Z 4.5 mm and day 28 Z 3 mm). Five patients had five
different adverse events, four reported as non-attributable
to the treatment. They involved two patients in the WCG
group: viral tonsillitis, rhinitis and, in the case of two
patients in the CG group, sinusitis and coronary syndrome.
The coronary syndrome occurred on day 4. There was good
recovery and the cardiologists did not consider that it was
related to the study treatment. One patient (WCG) pre-
sented with visual disturbance (scotoma) immediately after
sclerotherapy but it resolved completely in less than
15 min.
Discussion
This randomised study confirms the efficacy and safety of
foam sclerotherapy in the treatment of saphenous veins,
evaluated here in the short term. On the one hand, for both
groups, with or without compression, the saphenous veinFigure 1 Thrombophlebitis on D28 (small saphenous vein
tributary).occlusion rate was 100%, with rare and benign side effects
and significant improvement in QOL. On the other hand, the
outcome showed no difference between the two treatment
groups. In particular, compression did not demonstrate the
expected superiority in the following areas: thrombophle-
bitis, inflammation, pain, pigmentation and matting. In
accordance with the recommendations of the experts,5 the
doses administered were small and this may account for the
low incidence of side effects.
Compression did not reduce endoluminal thrombus
forming after sclerotherapy since the average diameter of
the occluded veins was the same in both groups. An early
systematic DUS examination revealed two minimal and
asymptomatic gastrocnemius vein thromboses in the CG
after SSV sclerotherapy. The prevalence of the muscular
thromboses post-sclerotherapy has probably been under-
estimated in the literature, but their early systematic
screening may be a subject for discussion. When they are
asymptomatic, they do not appear to require any particular
measures.
Only one randomised study in the literature has
compared sclerotherapy with or without compression. ThisFigure 2 Thrombectomy on D28 (thrombophlebitis).
506 C.M. Hamel-Desnos et al.trial involved telangiectases and reticular veins and
concluded that the results were better for the compression
group (23e32 mmHg for 3 weeks) in the opinion of inde-
pendent experts undertaking blinded assessments of
photographs.9 The patient satisfaction score, however,
showed no difference that would permit a distinction to be
made between the two groups.
In the management of reticular veins and telangiectases
following sclerotherapy, it has been suggested that
30e40 mmHg compression stockings are worn for a week
followed by a 20e30 mmHg compression for 3 weeks.10
However, there is very limited evidence for the efficacy of
this strategy and this does not seem to justify imposing such
measures on a large scale. The expected benefit should be
at least equal to the constraint, which is particularly high in
this protocol, and ought to be genuinely demonstrated.
We decided to use a 15e20 mmHg compression level in
our trial because it is the most common compression class
used following sclerotherapy in France. This compression
probably exerts too low a pressure on the saphenous veins
to modify their diameter. It is unlikely that a stronger class
of stocking would significantly alter the results of our study,
in which we observed a low incidence of side effects
following treatment. The use of stronger stockings may also
lead to the patients inadvertently performing a Valsalva
manoeuvre, which may be a factor leading to systemic side
effects after foam injections.7
When applying elastic compression stockings, the prac-
titioner needs the patient’s co-operation; even so, it is
difficult to avoid Valsalva manoeuvres when applying
15e20 mmHg stockings but quite impossible with
30e40 mmHg stockings. Elastic bandages are sometimes
used; nevertheless, a consensus of experts recommends
elastic stockings rather than bandages.11
Eccentric compression with a newly developed wedge-
shaped device (Medi postop Medi Bayreuth, Germany),
combined with thigh length stockings (Struwa 35, Medi
Bayreuth, Germany), has been proposed with the aim of
preventing the formation of endoluminal thrombus in the
saphenous trunk.12 This system has the ability to apply
much higher levels of compression over the treated vein, to
the extent that the saphenous diameter is greatly reduced.
Clinical trials have yet to be done to confirm that value of
this type of compression following sclerotherapy.
The abolition of thrombus from a vein following scle-
rotherapy may be difficult, or impossible, to achieve. Serial
ultrasound imaging of saphenous veins following chemical
or thermal ablation shows a transition to fibrosis, healing
and disappearance of the vein from a starting point of
endoluminal thrombus. This process may take several
months or even 1 or 2 years.4
Inflammatory and painful reactions and thrombo-
phlebitis occur more frequently in the tributaries than in
the saphenous trunks themselves. It has yet to be
demonstrated that more rigorous compression will avoid
thrombophlebitis.
In our trial, the mean number of days for which elastic
compression was worn was 11 out of 21 days for which
patients should have worn stockings. Only 40% of patients
wore compression stockings every day. Compliance with
compression (and its assessment) is a limitation of this
treatment. Our experience of poor compliance is consistentwith what has been reported previously in venous diseases
in general.13
It should be noted that use of compression after scle-
rotherapy has long varied according to the country in which
it is practiced.14 The ‘sclerotherapy cultures’ have differed
historically (school of Tournay and compressionescle-
rotherapy of Fegan and Sigg), and regarding doses and
choice of sites of injections, some practices may provoke
more local side effects than others. The cultures of the
patients are equally diverse, their discipline and perception
of bodily image varying depending on country and region,
where climates may also differ. All these factors, added to
the variability of the materials and individual practitioners’
habits, have limited the uniformity of practice and render it
quite complex to assess the usefulness of compression.
Finally, our study shows that compression stockings do
not prevent side effects arising from foam sclerotherapy
and do not seem to improve its efficacy in the short term.
Compression treatment may be useful in the manage-
ment of thrombophlebitis following sclerotherapy, but this
was not evaluated in our trial. Achieving effective obliter-
ation of veins while avoiding an excessive dose of sclerosant
is probably the most difficult aspect of sclerotherapy,
together with the choice of sites of injection. Practitioners
should focus on this main target.
Conclusion
The importance of elastic compression in chronic venous
disorders has neither been studied nor challenged in this
article, which merely studied the impact of compression on
sclerotherapy. We found that the additional use of
compression stockings following ultrasound-guided foam
sclerotherapy made no difference to the outcome measures
of effectiveness of obliteration of veins, side effects,
satisfaction score, symptoms and QOL. Further controlled
studies of compression are required to assess the role of
compression in sclerotherapy and to evaluate other
compression strategies. Much of current practice in phle-
bology is based on the opinions of experts rather than level
1 scientific evidence from clinical trials, a failing which
should be addressed.
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